u/sigrid_kaufmann

the sequence is the product, everything else is packaging

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

Careful — that arithmetic is wrong. 10mg in 3mL is 3.33mg/mL, so 0.5mg draws to 15 units, not what you wrote.

Asked for identity confirmation on an unusual line and got a mass spectrum with the theoretical mass alongside. That is the answer I now look for everywhere.

What did the intake actually ask you?

That is sterile water, not bacteriostatic. Same appearance, different product, and it matters for a multi-draw vial.

Push back: approval by the national regulator says nothing about whether any plan will pay.

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

units are a volume on a U-100 syringe, not a dose

Kept every form and reference number. When they had no record of a submission, I did.

Not quite. Bacteriostatic and sterile water are not interchangeable for a multi-draw vial, and the difference is the preservative.

Identity confirmed, or purity only?

the fasting number is the one people fixate on and it moves last

text only here, by community rule, and it works better than you would think

a single high reading is not a trend

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

That figure is the starting material purity, not the finished preparation potency. Two different tests.

the API source is the question nobody asks and everybody should

the same product can be covered in one province and not the next

Agreed on the swirl.

Right, and the arithmetic behind it: 15mg in 3mL is 5mg/mL, so 0.5mg is 10 units.

ask which lines are actually stocked rather than made to order

What lead time were you quoted for that line?

Disagreeing with this bit: handling for one compound does not transfer to another by default.

A certificate of analysis is a document describing one batch: what was tested, by what method, and what the result was. Its value depends entirely on whether it names the batch and the method.

Agreed. Network first, address second, amount third, and in that order every time.

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

Did the clothes change before the number did for you too?

Continuous monitoring shows the shape: postprandial excursions, overnight behaviour and time in range. Two people with identical A1c can have very different distributions.

Has anyone here tested that compound at all?

I would not treat a two-kilo range as a regain. Weight varies day to day in everybody.

Agreed on variability. Two people with the same average can have completely different days.

I confused two very similar words on my first order and asked here, expecting to be mocked. Three people explained it properly instead.

send a test amount first if the total is large

Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

I would not treat catalogue breadth as a quality signal. It is a business decision, not an analytical one.

Agreed on keeping every form and date. When something goes wrong the paper trail is the whole case.

dead space in the needle hub is real and it is small

A goal weight chosen before starting is a prediction made with the least information you will ever have. Revising it is ordinary rather than a failure.

compare cash prices before assuming coverage is the only path

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.